Compare Applovin Corporation (APP) vs TG Therapeutics Inc (TGTX) Price & Performance

AppLovin (APP) trades at $303.76, down 10.4% in the last 24 hours, reflecting recent bearish sentiment driven by a Q2 earnings miss and a Bank of America downgrade. Despite strong fundamentals with 53% revenue growth in Q2 2026 and a net income margin of 64.58%, technical indicators show a bearish trend with the current price below key support levels. The stock faces near-term pressure from concerns over sustainable growth, though analyst consensus remains largely bullish with an average price target of $556.53.

The outlook for APP hinges on its ability to maintain high growth rates amid execution risks. While valuation multiples like a P/E of 24.5 appear reasonable given profitability, investors face volatility from competitive threats and model-dependent revenue growth. The stock offers upside if Q3 results beat expectations, but caution is warranted due to recent institutional selling and mixed technical signals.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.